UniProtKB/Swiss-Prot P63000: Variant p.Phe28Leu

• Variant information
• Sequence information
• Literature citations
• All

Variant information

Variant position: 28 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: LB/B The variants are classified into three categories: LP/P, LB/B and US.

• LP/P: likely pathogenic or pathogenic.
• LB/B: likely benign or benign.
• US: uncertain significance

Residue change: From Phenylalanine (F) to Leucine (L) at position 28 (F28L, p.Phe28Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: Change from large size and aromatic (F) to medium size and hydrophobic (L) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

• Lowest score: -4 (low probability of substitution).
• Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources: Links to websites of interest for the variant.

• Variant rs2115193183 [ dbSNP | Ensembl ]

Sequence information

Variant position: 28 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 192 The length of the canonical sequence.
Location on the sequence: VVGDGAVGKTCLLISYTTNA F PGEYIPTVFDNYSANVMVDG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

• Type: the type of sequence feature.
• Positions: endpoints of the sequence feature.
• Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 189	Ras-related C3 botulinum toxin substrate 1
Modified residue	32 – 32	(Microbial infection) O-AMP-tyrosine; by Haemophilus IbpA; alternate
Modified residue	35 – 35	(Microbial infection) O-AMP-threonine; by Vibrio VopS
Glycosylation	32 – 32	(Microbial infection) O-linked (GlcNAc) tyrosine; by Photorhabdus PAU_02230; alternate
Glycosylation	35 – 35	(Microbial infection) O-alpha-linked (GlcNAc) threonine; by C.novyi toxin TcdA; alternate
Glycosylation	35 – 35	(Microbial infection) O-linked (Glc) threonine; by C.difficile toxins TcdA and TcdB, and by P.sordellii toxin TcsL; alternate
Mutagenesis	12 – 12	G -> V. Constitutively active. Interacts with PARD6 proteins. Increases nuclear localization and up-regulates transcriptional activity of NR3C2. Doesn't interact with CYRIB. Increases interaction with GARRE1.
Mutagenesis	17 – 17	T -> N. Constitutively inactivated. Abolishes interaction with PARD6 proteins. No effect on NR3C2 transcriptional activity. No interaction with PPP5C. Doesn't activate PPP5C phosphatase activity and translocate PPP5C to the plasma membrane. Doesn't interact with CYRIB.
Mutagenesis	30 – 30	G -> V. No interaction with PPP5C; when associated with L-61. Translocates to the plasma membrane; also when associated with L-61.
Mutagenesis	32 – 32	Y -> F. Abolishes AMPylation by Haemophilus IbpA.
Mutagenesis	35 – 35	T -> A. Abolishes AMPylation by Vibrio VopS.
Mutagenesis	35 – 35	T -> S. No interaction with PPP5C; when associated with L-61. Translocates to the plasma membrane; also when associated with L-61.
Mutagenesis	37 – 37	F -> A. Strongly reduced interaction with PLCB2.

Literature citations

No reference for the current variant in UniProtKB/Swiss-Prot.